Statera BioPharma, Biostax reach dispute settlement, amended license agreement

Immune Therapeutics and Statera Biopharma announced that the Board of Directors of both companies has approved both a joint petition to dismiss the involuntary bankruptcy case with Statera and an amended royalty-bearing license agreement between Biostax and Statera for select Statera intellectual property. Under Amendment No. 3 to the License Agreement, Biostax will pay royalties to Statera and obtain worldwide exclusive rights to numerous patents surrounding Low-dose Naltrexone and Met-enkephalin, for all indications except Crohn’s Disease, which Statera will continue to develop and commercialize. .